Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase 2 blood-pressure endpoints, FDA meeting timelines, stock-based compensation for a science-driven team—Mineralys Therapeutics’ SEC disclosures are packed with biotech jargon that can overwhelm even seasoned analysts. If you have ever scrolled through a 300-page report looking for a single dosing update, you know the challenge. That complexity makes Mineralys Therapeutics insider trading Form 4 transactions and clinical milestones difficult to spot when seconds matter.
Stock Titan solves the problem. Our AI reads every Mineralys Therapeutics quarterly earnings report 10-Q filing the moment it hits EDGAR, extracts cash-runway tables, and flags enrollment progress so you don’t have to. It highlights Mineralys Therapeutics Form 4 insider transactions real-time, translates risk-factor language into plain English, and stitches together cross-references so you get Mineralys Therapeutics SEC filings explained simply. Whether you need a quick Mineralys Therapeutics earnings report filing analysis or are understanding Mineralys Therapeutics SEC documents with AI before a meeting, our platform delivers.
Use the dashboard to monitor upcoming trials stated in the Mineralys Therapeutics annual report 10-K simplified, drill into pipeline funding clues hidden in the Mineralys Therapeutics proxy statement executive compensation, or receive instant alerts when an executive executes Mineralys Therapeutics executive stock transactions Form 4. Material study readouts? They surface through Mineralys Therapeutics 8-K material events explained. Real-time updates, concise AI-powered summaries, and form-specific filters turn dense documents into actionable insights—freeing you to focus on whether lorundrostat’s next data cut could move the share price.
Mineralys Therapeutics, Inc. (MLYS) has filed a Form 144 indicating a planned sale of 15,884 common shares through broker Merrill Lynch. Based on the stated aggregate market value, the transaction is valued at approximately $230,430. The shares were acquired on 07/10/2025 via the vesting of a restricted stock unit award granted under the company’s equity-compensation plan and are expected to be sold on or after 07/11/2025 on the NASDAQ.
The filing shows 65,175,287 shares outstanding; the proposed sale therefore represents roughly 0.02 % of total shares. No other sales by the filer have occurred in the past three months, and no material adverse information was asserted in the certification section.
Mineralys Therapeutics, Inc. (MLYS) – Form 144 filing
The notice discloses a proposed Rule 144 sale of 10,758 common shares by an insider who received the stock through the vesting of a restricted stock-unit (RSU) award on 07 / 10 / 2025. The seller has engaged Merrill Lynch as broker and intends to sell the shares on the NASDAQ around 07 / 11 / 2025. At the recent market price used in the form, the transaction is valued at $155,454.
Given the issuer’s 65.18 million shares outstanding, the proposed sale represents roughly 0.02 % of total shares, indicating an immaterial ownership impact. The filer reports no other sales in the past three months and makes the customary representation that no undisclosed material adverse information is known.
Rule 144 filings signal possible insider sales but do not guarantee execution; actual trades depend on market conditions and compliance with Rule 144 volume and manner-of-sale limitations. For investors, the filing is primarily a routine administrative disclosure with negligible dilution risk.
FAQ
What is the current stock price of Mineralys Therapeutics (MLYS)?
What is the market cap of Mineralys Therapeutics (MLYS)?
What is the primary focus of Mineralys Therapeutics?
What is lorundrostat and how does it work?
Which therapeutic areas are covered by Mineralys Therapeutics' pipeline?
How does Mineralys Therapeutics differentiate itself in the hypertension market?
What is the significance of dysregulated aldosterone in hypertension?
What type of clinical trials are being conducted by Mineralys Therapeutics?
